Azacitidine: A Review of its Use in the Management of Myelodysplastic Syndromes
Clinical Medicine. Therapeutics · 2009
DOI: 10.4137/cmt.s1163 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Medicine. Therapeutics, 2009. Verfasst von Philip E. Lammers und 1 weiteren Autor:innen. Die Arbeit nennt 38 Literaturangaben.
Abstract (Originalsprache)
Myelodysplastic syndromes (MDS) are marked by progressive cytopenias and risk of transformation to acute myeloid leukemia. Supportive care with transfusions, antibiotics, and hematopoietic growth factors has long been the mainstay of therapy for MDS, given that most patients are not eligible for more intensive chemotherapy. The hypomethylating agent 5-azacitidine (AZA) was the first chemotherapeutic agent approved by the U.S. Food and Drug Administration for the treatment of MDS, and it represented a real advance in the management of the disease. In Phase III trials, azacitidine demonstrated a higher response rate and a longer overall survival compared to supportive care alone. Importantly, it is a well-tolerated drug that can be given IV or SC in various outpatient schedules. Future studies are expected to evaluate the activity of AZA in combination with other epigenetic modifying agents and to establish the relative efficacy of azacitidine and decitabine. This review summarizes the current treatment landscape in MDS and specifically addresses the role of azacitidine in the management of MDS.
Zitieren
APA
Lammers, P. E., & Cashen, A. F. (2009). Azacitidine: A Review of its Use in the Management of Myelodysplastic Syndromes. Clinical Medicine. Therapeutics. https://doi.org/10.4137/cmt.s1163
Vancouver
Lammers PE, Cashen AF. Azacitidine: A Review of its Use in the Management of Myelodysplastic Syndromes. Clinical Medicine. Therapeutics. 2009. doi:10.4137/cmt.s1163
BibTeX
@article{Lammers2009,
author = {Lammers, Philip E. and Cashen, Amanda F.},
title = {Azacitidine: A Review of its Use in the Management of Myelodysplastic Syndromes},
journal = {Clinical Medicine. Therapeutics},
year = {2009},
doi = {10.4137/cmt.s1163}
}
EUVIMED